

## **Sunesis Pharmaceuticals to Present at C.E. Unterberg, Towbin Life Sciences Conference**

October 21, 2005 12:23 PM ET

SOUTH SAN FRANCISCO, Calif., Oct 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that Daniel N. Swisher, Jr., Chief Executive Officer and President, is scheduled to present a corporate update at the upcoming C.E. Unterberg, Towbin Life Sciences Conference. The presentation is scheduled for October 25, 2005 at 9 a.m. at the Palace Hotel, New York, NY.

Interested parties may access the webcast of the presentation by visiting the Sunesis website at [www.sunesis.com](http://www.sunesis.com). A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until November 8, 2005.

### **About Sunesis Pharmaceuticals**

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit [www.sunesis.com](http://www.sunesis.com).

### **Forward-Looking Statements**

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

### **SOURCE Sunesis Pharmaceuticals, Inc.**

investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman or Michelle Corral of BCC Partners, +1-650-575-1509, or +1-415-794-8662

<http://www.prnewswire.com>

Copyright (C) 2005 PR Newswire. All rights reserved.

News Provided by COMTEX